USA –
LOS ALTOS, CA, Evommune announced the successful completion of a $12.5 million seed financing.
Evommune, Inc., an innovation engine in chronic inflammation, announced the successful completion of a $12.5 million seed financing by Pivotal bioVenture Partners. This financing will enable Evommune to build a pipeline of unique therapies for patients with chronic inflammatory diseases.
Evommune is a private, R&D company and innovation engine in chronic inflammation. Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases. Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases. The company is headquartered in Los Altos, California.
Evommune
Los Altos, CA
